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Breast cancer is the most common malignant neoplasm in women. The presence of 
hormone receptors on malignant cells influences the prognosis and application of the 
appropriate therapy. The receptor status of estrogen and proestrogen was tested in 
relation to the age of the patients and clinical stage of disease. The analysis comprised 449 
patients with breast cancer, with mean age 56.2±12 years, treated at the Oncology Clinic 
CC Nis and operated at the Surgery Clinic CC Nis, separated into four groups: I group - 
246 patients with ER+/PR+ receptors; II group - 45 patients with ER+/PR- receptors; III 
group - 20 patients with ER-/PR+ receptors and IV group - 109 patients with ER-/PR- 
receptors. The clinical stage of the tumor was described as operable, locally advanced and 
metastasis, plus patient age stratification. The receptor status was determined in 440 
patients, while it remained unknown in 9(2%) cases. In regard to the total number of 
patients, ER+/PR+ is registered in 54.7%, ER+/PR- in 14.0%, ER-/PR+ in 4.5%, and 
24.3% in ER-/PR-. The most common is a hormone-sensitive breast tumor (76%) in 
regard to non-sensitive tumors (24%). From hormone-sensitive tumors, the most common 
were Er+/Pr+ tumors with 58%, and the least common Er-/Pr+ tumors with 4%. In 
women younger than 40, hormone non-sensitivity dominates (55%). Hormone-sensitive 
tumors are more present as the patients are older, and they dominate in patients older 
than 70. Operable tumors were found in 78.64% of women, locally advanced in 18.18%, 
and metastasis in 3.18%. Hormone-sensitive tumors are far more often operable and less 
locally advanced than non-sensitive tumors (Hi=8.2, p<0.01). Metastatic tumors did not 
show any significant difference in hormone sensitivity. Acta Medica Medianae 2007; 
46(2):25-30. 
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Introduction 
 
Breast cancer is one of the biggest health 
concerns for women. That kind of fear is justified 
by the fact that breast cancer is the most 
common sort of malignant tumor which often 
develops insidiously in the form of a painless 
tumor and without subjective pains. The patient 
and her surroundings considerate as a severe 
and undeserved punishment which leads to a 
fatal outcome after a lot of suffering and 
difficulties. It represents the most common mali-
gnant tumor in women worldwide and comprises 
20% of all neoplasms in women in Europe. Breast 
cancer is a big social/medical issue/problem 
because of its frequency and consequences. 
There are 10 million people in the world 
who fall down with cancer every year. Lung 
cancer is the most common (1.350.000 new 
patients a year), breast cancer (1.115.000 of 
women a year) and colon cancer (about a million 
people). There are huge geographic differences in 
the number of newly discovered cases, so the 
there are high risk countries (Northern America 
and Northern Europe), moderate risk countries 
(Southern America and Southern Europe) and 
low risk countries (Asia and Africa) (1). 
According to the Cancer Register of Central 
Serbia (2) and the Malignant Neoplasm Register 
of Vojvodina (3), there are 30 000 people in 
whom cancer is discovered every year in Serbia. 
Breast cancer is the most common malignant 
neoplasm in women and is of great importance 
because of continual increase of incidence and 
mortality. There are about 4000 new cases 
registered and about 1300 women die (4, 5) each 
year. Latest statistics show mortality stagnation 
in regard to morbidity in most countries in the 
world which is explained by contemporary 
detection and treatment methods.  
There are numerous breast cancer risks 
which can act pretty early (initiators) and/or later 
(promoters). The most important are: age, older 
women who are giving birth to the first child 
(after 30 years of age), genetic, nutritive and 
hormone factors, previous breast cancer, 
changes in breasts (atypical hyperplasia or 
lobular carcinoma in situ), environment factors 
(radiation). Despite breast cancer risk factors 
being known, in 50% of women they are not Hormone sensitivity of tumor in women with breast cancer                             Ivana Pesic et al. 
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detected (5). Genetic factors (BRCA1 and BRCA2 
tumor suppressor gene mutation) are responsible 
for 5-10% breast cancer cases. It is not possible 
to influence the most important risk factors, such 
as age and genetic factors, but is possible, to 
some extent, to influence the reproductive and 
hormone factors by »healthy way of life« which 
means healthy nourishment with body weight 
regulation and regular physical activities.   
Breast cancer is a hormone-dependant 
tumor prototype and 1/3 of the patients will 
positively respond to the endocrine therapy. In 
evaluation of hormone-sensitivity degree, impor-
tant factors are estrogen receptors (ER) and 
proestrogen receptors (PR), for there are new 
treatment possibilities by applying medicaments 
which »block« the receptors. The importance of 
their determination is stressed by the latest 
references for individual therapy approach in 
breast cancer patients (6). 
Having in mind that breast cancer risk can 
not be eliminated, secondary prevention is nece-
ssary which includes early detection pro-grams 
and screening programs. Screening means an 
organized application of the screening test in 
healthy population and opening of illness cases 
which are still not recognizable (7). Programs for 
early detection aim at: health enlightenment of 
people, education of health care workers, refe-
rences for early detection, etc. 
For breasts of younger women, an impor-
tant diagnostic method (after the physical exa-
mination) is the ultrasound, because its sensiti-
vity and characteristics at that stage are higher 
than mammography. The reason for this is the 
fact that the majority of the breast size in gene-
rative stage represents a hyperechogenous glade 
tissue, while in the menopause the gland and the 
parenchyma are replaced with hypoechogenous 
fatty tissue. In older women they are comple-
mentary, but because of the examination being a 
simple one and satisfactory sensitivity, mammo-
graphy is preferred.  
According to the EU references, breast 
screening should be done by mammography 
examination of women aged 50-69 years each 2-
3 years by organized invitation and monitoring of 
women. Mammography is a breast x-ray used for 
more precise confirmation of changes in the 
breast tissue, as well as for detection of those 
minor changes which can not be registered 
during the palpable examination. Application of 
this screening in Europe and the USA reduced 
mortality by 20-30 %. 
 
 Aims 
 
Having in mind breast cancer being so 
frequent, morbidity and mortality in women and 
the predictive importance of the hormone status 
for the prognosis of the illness and application of 
the appropriate therapy, the objective was to 
determine the estrogen and proestrogen receptor 
status in regard to age of the patients and clinical 
stage of disease. 
Material and methods 
 
The general method is comparing of data 
acquired by retrospective analysis of medical 
documents and hospital registers.  
There were 449 breast cancer patients 
analyzed, operated at the Surgery Clinic CC Nis, 
who carried on with their treatment at Oncology 
Clinic CC Nis. 
According to the hormonal status, all 
patients were divided into four groups: 
•  I group -  246 patients with ER+/PR+ recep-
tors 
•  II group - 45 patients with ER+/PR- receptors 
•  III group - 20 patients with ER-/PR+ recep-
tors 
•  IV group - 109 patients with ER-/PR- recep-
tors. 
During data analysis, patients were classi-
fied by age, and those younger than 36 years of 
age were specially dealt with at the moment of 
giving the diagnosis.   
Patients from all four groups were analyzed 
in regard to the clinical tumor stage, defined as 
operable, locally advanced or metastasis.  
All participants were analyzed at the Onco-
logy Clinic CC Nis. The observation study compri-
sed patients treated at the Clinic from January 
2003 to December 2005.  
Data were processed by using standard 
descriptive statistic methods (mean value, stan-
dard deviation and percentage). The results were 
analyzed by using appropriate tests, depending 
on the size of the group, type of indication and 
distribution type. The strategic processing was 
done within and among defined groups.  
There were several test types: Student t 
test for pared and non-pared causes, Hi
2 test, 
Mantzel Haencel test and Fisher test of exact 
probability.  
Statistics was done by the use of Excel 7.0 
and SPSS 11.0 in Windows 98 operative system, 
which presented data through tables and 
diagrams. 
 
Results 
 
Within three-year period of monitoring 
(2003-2005) at the Oncology Clinic, there were 
449 breast cancer patients treated. The receptor 
status was determined in 440 patients, but it was 
unknown in 9 (2%) patients. In regard to the 
total number of analyzed patients, ER+/PR+ was 
registered in 54.7%, ER+/PR- in 14.0%, ER-/PR+ 
in 4.5% and 24.3% of patients was not hormone 
sensitive. General data of the examined patients 
and hormone sensitivity to disease is shown in 
Table 1. 
Average age of the breast cancer patients 
is 56.2±12 years, and Student T-test did not 
show any significant difference concerning the 
age of the patients which belong to analyzed 
groups. Non-parametrical analysis of Mantzel 
Haencel test did not either confirm any difference 
concerning the place of living (Table 1). Acta Medica Medianae 2007,Vol.46    Hormone sensitivity of tumor in women with breast cancer 
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Table 1. General data of the examined patients 
 
Place   Receptor 
characteristics 
No. (%) 
Age 
(years)  City Village 
Er+/Pr+ 246  54.7  55.5±11.9  154 92 
Er+/Pr- 65  14.5  57.4±9.02  46 19 
Er-/Pr+ 20  4.5  54.2±15.1  9 11 
Er-/Pr- 109  24.3  57.6±11.9  65 44 
Not specified  9  2.0  67.4±7.7  4 5 
total 449  100.0  56.2±12  278 171 
 
 
Table 2. Clinic stages and receptor status  
 
Stage Er+/Pr+  Er+/Pr-  Er-/Pr+  Er-/Pr-  Total 
Operative  207  49 16 74  346 
Locally advanced  33 13  4  30 80 
Metastasis  6 3 0 5  14 
Total  246 65  20 109  440 
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Diagram 1. Hormone status and age of patients with primary breast cancer  
 
 
 
Diagram 2. Clinical stage and tumor hormone status  
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In analyzed women breast hormone 
sensitive tumor was the most common one 
(ER+/PR+, ER+/PR-, ER-/PR+) (76%) in regard 
to non-sensitive (Er-/Pr-) tumors (24%). From 
hormone sensitive, mostly there were the 
Er+/Pr+ tumors presented with 58%, while the 
least frequent was Er-/Pr+ tumor, presented with 
only 4% ,.  
Age structure of the patients and the 
combination frequency of hormone status with 
the rise in regard to age of the patients is shown 
in Diagram 1. 
From Diagram 1 one can see that the 
majority of the patients were in the group aged 
40-49 and 60-69. The least number of patients 
was in the group of 80-89 years of age. 
It is notable that in women younger than 
40 years of age, hormone non-sensitivity 
dominates, and is present in about 55% of all 
cases. As the age advances, the frequency of the 
hormone non-sensitive tumors falls, while the 
number of the hormone sensitive tumors, which 
completely dominate in patients older than 70 
years of age, rises.    
Number of patients and their receptor 
status in regard to the clinical stage of disease in 
breast cancer is shown in Table 2. Operable 
tumors were found in 78.64%, locally advanced 
in 18.18%, and metastasis in 3.18%. 
The variance analysis shows that there is a 
significant difference in the frequency of clinical 
stages among patient groups with different 
receptor combinations (F=3.75, p<0.05). Post-
hoc analysis shows that there is the difference 
among groups with ER+/PR+ and ER-/PR- 
(Tuckey HSD, p<0.05), i.e. ER+/PR+ tumors 
were more often operable (Table 2). 
Hormone sensitivity and clinical stages of 
disease are shown in Diagram 2.  
Hormone sensitive tumors (ER+/PR+, 
ER+/PR-, ER-/PR+) were operable in 82.2% and 
locally advanced in 15.1%. Non-sensitive tumors 
were operable in 67.9% and locally advanced in 
27.5%. Mantzel- Haencel test confirmed that 
hormone sensitive tumors are considerably more 
often operable, less likely locally advanced than 
non-sensitive tumors (Hi=8.2 p<0.01). Metasta-
sis tumors did not show any significant difference 
in hormone sensitivity (p=NS) (Diagram 2). 
 
Discussion 
 
Breast cancer, having in mind its epidemic 
and biological characteristics, is the most 
important malignant disease in women. Each 
year, there are 4000 women registered with 
breast cancer in Serbia and 1300 die.    
World Health Organization estimates that in 
this century every 8th woman on the planet will 
have this illness. The number of the newly 
registered is in constant increase and it amounts 
to 1-2% a year worldwide, while in our country, 
that number have increased this year by 10% in 
regard to 2003. Incidence spike is more and 
more moving towards younger women. Ten years 
ago, breast cancer was discovered in women 
aged about 65 years and today about 55 years. 
According to the Institute of Oncology and 
Radiology in Belgrade, the mean of patients is 56 
years and it is identical to the mean age of our 
patients. Women with breast cancer in the USA, 
Australia, South American countries, etc. are of 
average age 50 years (8).  
An important prognostic and predictive 
factor of breast cancer is estrogen and 
proestrogen receptor status. Majority of receptors 
indicate a positive response to endocrine therapy. 
About 70% of primary breast cancer have 
positive estrogen receptors, while 30% are 
negative (9). Positive receptor status correlates 
with favorable prognostic characteristics, 
including a low level of cell proliferation and 
histological proof of tumor differentiation (10). 
Results of various studies show that about 
70% of the primary breast cancer express 
estrogen receptors, while 30% are ER-negative 
(11), which is not vastly different from the 
results of women in our study, where ER+ 
69.27%, ER- 30.73% and PR+ 4.45 %. 
Lower level of expression ER+ 32.1% in 
breast cancer is found in women in India. This 
can be partially explained by breast cancer being 
more frequent in younger women with high grade 
of tumor, for they are almost ten years younger 
than in Western countries (12). On the contrary, 
Lou's studies from China result in 73, 5% ER+ 
and 65, 5 % PR+. 
The published results of Barns and his 
associates in European population is about 50% 
of cancer ER+/PR+, 25% is ER-/PR-, 20% is 
ER+/PR- and about 5% is ER-/PR+. Our results 
are not significantly different apart from 
(ER+/PR- 15% and ER+/PR+ 55%).  
There is an unusual result of the research 
conducted in India which allows a high level of 
proestrogen receptors ER-/PR+ (21,1% compa-
red to 5%). This model of a receptor status was 
significant in patients with soft tissue and 
metastasis of CNS. The results confirm that this 
is a biologically and clinically defined subgroup 
which requires further detailed analysis and 
estimates (3). 
In our group ER+/PR+ cancer amounted to 
55%, with significantly higher presence of 70,3% 
in patients over 50 years of age in regard to the 
data from the literature which shows 49%, which 
can be explained by the number of patients 
included in the research. The concentration of 
ER-/PR- was more visible in younger patients, 
which correlates with the literature data.  
Positive breast cancer receptors are more 
often in postmenopause - 80, 3%, while the 
receptor of the negative is more often found in 
younger age groups - 41, 2%. This result finding 
is a result of differences in hormone status or 
biologic differences of cancer of observed patient 
groups. Higher presence of concentration ER-
/PR+ of the primary breast cancer in post-
menopause in regard to premenopause can be 
the result of higher concentration of estrogens 
and higher saturation ER of endogen  estradiol 
(14). Acta Medica Medianae 2007,Vol.46    Hormone sensitivity of tumor in women with breast cancer 
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Operable cancers are ER+ in 78, 6% in 
regard to ER- 21, 4%, while locally advanced are 
ER+ 62, 5%, and metastasis 64, 2%. Data from 
the literature show that the size of tumor does 
not correlate with ER/PR status (15). 
Breast cancer in younger patients is, acco-
rding to conducted research results, significantly 
more aggressive. It is usually detected in the 
advanced stage and requires aggressive therapy. 
One of the reasons for bad diagnosis is that in 
patients of this age, the more common receptor 
is negative breast cancer which is not sensitive to 
hormone therapy.    
There were only 27 (6%) women in our 
research younger than 40 operated from breast 
cancer with ER/PR status. From the total number 
of the patients with receptors, 70, 3% were 
hormone sensitive, which is statistically signifi-
cant and does not correspond to data from many 
studies. The reason for this may be a small 
number of patients in the research group, but 
also the criteria for detecting positive cancers’ 
receptor, which are modified and in a great num-
ber of studies represent only an evident expre-
ssion ER cancers (16).  
There are data in the literature which show a 
favorable therapeutic effect of the hormone the-
rapy in 10% negative receptor cancers (17), which 
is explained by an extra receptor, insufficiently 
explained mechanism of hormone therapy. 
 
Conclusion 
 
•  The level of steroid estrogen and proe-
strogen breast cancer receptors is in positive 
correlation with patients' age. 
•  There is no statistically significant diffe-
rence concerning the patients age of the rese-
arched groups.  
•  Positive ER/PR is significantly present in 
postmenopause patients, contrary to negativity in 
premenopause. 
•  Operable cancers are receptor ER positive 
in 78,6% cases, in regard to receptor ER nega-
tive (21,4%). 
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HORMONSKA SENZITIVNOST TUMORA KOD BOLESNICA SA RAKOM 
DOJKE  
 
Ivana Pešić, Miloš Krstić, Miljana Pavlović, Dejan Ilić i Kontsmans Dimitrios 
 
 
Karcinom dojke je najčešća maligna neoplazma kod žena. Prisustvo hormonskih 
receptora na malignim ćelijama utiče na prognozu i primenu adekvatne terapije. U radu je 
ispitivan estrogen i progesteron receptorski status u odnosu na starost bolesnica i klinički 
stadijum bolesti. Analizirano je 449 bolesnica obolelih od karcinoma dojke, prosečne 
starosti 56.2±12 godina, lečenih na Klinici za onkologiju KC Niš i operisanih na Klinici za 
hirurgiju KC Niš, podeljene u četiri grupe: I grupa - 246 bolesnica sa ER+/PR+ 
receptorima; II grupa - 45 bolesnica sa ER+/PR- receptorima; III grupa - 20 bolesnica sa 
ER-/PR+ receptorima i IV grupa - 109 bolesnica sa ER-/PR- receptorima. Klinički stadijum 
tumora je definisan kao operabilni, lokalno uznapredovali i metastatski, pri čemu je 
izvršena i starosna stratifikacija bolesnica. Receptorski status je određen kod 440 
bolesnica, dok kod 9(2%) nije poznat. U odnosu na ukupan broj ispitanica ER+/PR+ je 
registrovan kod 54.7%, ER+/PR- kod 14.0%, ER-/PR+ kod 4.5%, a 24.3% kod ER-/PR-. 
Najčešće je zastupljen hormonosenzitivni tumor dojke (76%) u odnosu na nesenzitivne 
tumore (24%). Od hormonosenzitivnih najčešće su bili zastupljeni Er+/Pr+ tumori sa 58%, 
a najređe Er-/Pr+ tumori sa 4%. Kod žena mlađih od 40 godina dominira hormonska 
nesenzitivnost (55%). Sa starošću bolesnica dolazi do porasta učestalosti hormono-
senzitivnih tumora, koji dominiraju kod bolesnica starijih od 70 godina. Operabilni tumor je 
nađen kod 78.64%, lokalno uznapredovali kod 18.18%, a metastatski kod 3.18%. 
Hormonosenzitivni tumori su značajno  češće operabilni a ređe lokalno uznapredovali od 
nesenzitivnih tumora (Hi=8.2, p<0.01). Metastatski tumori nisu pokazivali značajniju 
razliku u hormonskoj senzitivnosti. Acta Medica Medianae 2007;46(2):25-30. 
 
Ključne reči: karcinom dojke, hormon senzitivni tumori, estrogen, progesteron 
 
 
 